HOWL vs. RANI

In the year-to-date period, HOWL achieves a -39.82% return, which is significantly lower than RANI's -18.25% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Werewolf Therapeutics, Inc. (HOWL) and Rani Therapeutics Holdings, Inc. (RANI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current HOWL Sharpe Ratio is -0.85, which is comparable to the RANI Sharpe Ratio of -0.77. The chart below compares the historical Sharpe Ratios of HOWL and RANI, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither HOWL nor RANI has paid dividends to shareholders.

The maximum HOWL drawdown since its inception was -96.90%, roughly equal to the maximum RANI drawdown of -96.97%. Use the drawdown chart below to compare losses from any high point for HOWL and RANI. For additional features, visit the drawdowns tool.

Werewolf Therapeutics, Inc. (HOWL) has a higher volatility of 38.41% compared to Rani Therapeutics Holdings, Inc. (RANI) at 32.01%. This indicates that HOWL's price experiences larger fluctuations and is considered to be riskier than RANI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Werewolf Therapeutics, Inc. and Rani Therapeutics Holdings, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.